Altegra, a resident of the Dubna Special Economic Zone (SEZ), completed construction of a workshop for solid dosage forms of beta-lactam antibiotics this year. The pharmaceutical company has already launched production of its first experimental batches. After receiving a license in the fall, Altegra plans to start mass production. Investments in the workshop amounted to about 200 million rubles, the press service of the Ministry of Investment, Industry and Science of the Moscow region reported.
The new site will expand the company’s product range to 40 items and increase annual production to 70 million capsules and around 150 million tablets. Ekaterina Zinovieva, Deputy Prime Minister and Minister of Investments of the Moscow region, said that after commissioning the workshop, the number of jobs at the enterprise increased to 160.
Altegra aims to obtain a license from the Ministry of Industry and Trade this fall, which will enable it to begin mass production for pharmacy chains. Previously, the company’s products were used only in medical institutions, including intensive care units.
Olga Turchaninova, General Director of AO Altegra, said, “Today, the enterprise has over 2,000 square meters of production facilities and 450 square meters of physico-chemical, microbiological, and R&D laboratories.” She noted that the company is continuously expanding its product line, having launched production of 34 drugs so far, with 24 more under development.
β-lactam antibiotics are antibiotics that contain a β-lactam ring in their chemical structure. This group includes penicillins, cephalosporins, carbapenems, and monobactams—key drugs in the fight against bacterial infections.
Earlier, it was reported that Altegra’s subsidiary, OOO Alsigma, will build a plant for antitumor drugs in the Dubna SEZ. Investments in the project are expected to reach 1.8 billion rubles.
